700M euros in German rebates paid, 300M to go

We've all heard the percentages from the German government: Health reforms boosted rebates by 10 percent in August, to 16 percent from 6 percent. The pricing move is designed to save Germany more than €1 billion by the end of this year--but it also puts the squeeze on drugmakers.

Over the first nine months of the year, pharma shelled out €700 million in rebates to the German government. So that leaves another €300 million to be paid by year's end. And this, of course, is just the beginning. More stringent price pressures kick in next year, including a broadening of the reference price system to cover more drugs. Starting in January, branded drugmakers will have to negotiate prices with the government's health insurance system.

An industry group in Germany warns that, while the price moves put the squeeze on Big Pharma, too, it's the small- and medium-sized companies that will suffer most. No word on whether the government plans to do anything about it.

- read the PharmaTimes story

Suggested Articles

Esperion's Nexletol has had a rough road to approval after safety concerns nearly derailed its quest. But an FDA nod has the drug ready for market.

In an interview with Israel's Calcalist, Teva CEO Kåre Schultz shared details of his approach to the company's turnaround.

Nerlynx is already struggling in its extended adjuvant breast cancer setting, and new entrants from Daiichi-AZ and SeaGen could pressure it elsewhere.